The estimated Net Worth of Jill Buck is at least 388 千$ dollars as of 8 January 2021. Ms. Buck owns over 27,894 units of Alaunos Therapeutics Inc stock worth over 173,579$ and over the last 5 years she sold ZIOP stock worth over 214,079$. In addition, she makes 0$ as Executive Vice President、 General Manager、 Gene Therapy at Alaunos Therapeutics Inc.
Sign up
Ms. Buck ZIOP stock SEC Form 4 insiders trading
Jill has made over 2 trades of the Alaunos Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 27,894 units of ZIOP stock worth 87,029$ on 8 January 2021.
The largest trade she's ever made was selling 27,923 units of Alaunos Therapeutics Inc stock on 2 January 2020 worth over 127,050$. On average, Jill trades about 13,954 units every 93 days since 2020. As of 8 January 2021 she still owns at least 199,516 units of Alaunos Therapeutics Inc stock.
You can see the complete history of Ms. Buck stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jill Buck biography
Jill Yannetti Buck serves as Executive Vice President, General Manager, Gene Therapy of the Company. Ms. Buck has served as our Executive Vice President, General Manager Gene Therapy since January 2019 and served as our Senior Vice President of Clinical Operations from January 2017 to January 2019, and as our Vice President of Clinical Operations from September 2015 to January 2017. Previously, Ms. Buck served as Group Vice President of Global Clinical Operations at Synageva Biopharm Corp from January 2014 to September of 2015, and Vice President of Global Clinical Operations from June 2013 to January 2014 where she oversaw the teams responsible for the clinical trials resulting in US, EU and Japanese approvals of sebelipase alfa for LAL Deficiency. Prior to Synageva, Ms. Buck held roles of increasing responsibility in Clinical Operations at the Company, Averion International, Control Delivery Systems and The TIMI Study Group at Brigham and Women’s Hospital. Ms. Buck holds a BA degree in English and Communications from Boston College.
How old is Jill Buck?
Jill Buck is 46, she's been the Executive Vice President、 General Manager、 Gene Therapy of Alaunos Therapeutics Inc since 2019. There are 16 older and 1 younger executives at Alaunos Therapeutics Inc. The oldest executive at Alaunos Therapeutics Inc is J. Kevin Buchi, 65, who is the Director.
What's Jill Buck's mailing address?
Jill's mailing address filed with the SEC is ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON, MA, 02129.
Insiders trading at Alaunos Therapeutics Inc
Over the last 19 years, insiders at Alaunos Therapeutics Inc have traded over 2,792,771$ worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth 39,823,909$ . The most active insiders traders include Randal J Kirk、Randal Jintrexon Corp Kirk、Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of 152,086$. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth 25,568$.
What does Alaunos Therapeutics Inc do?
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
What does Alaunos Therapeutics Inc's logo look like?
Complete history of Ms. Buck stock trades at Alaunos Therapeutics Inc
Alaunos Therapeutics Inc executives and stock owners
Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Laurence Cooper,
Chief Executive Officer, Director -
Satyavrat Shukla,
Chief Financial Officer -
Robert Hadfield,
Executive Vice President, Chief Compliance Officer, General Counsel, Secretary -
Kevin Lafond,
Senior Vice President - Finance, Chief Accounting Officer, Treasurer -
Heidi Hagen,
Independent Director -
Dr. Eleanor de Groot Ph.D.,
Exec. VP of Operations -
Christopher Bowden,
Independent Director -
Scott Tarriff,
Independent Chairman of the Board -
Dr. Raffaele Baffa M.D., Ph.D.,
Chief Medical Officer and Exec. VP of R&D -
Elan Ezickson,
Independent Director -
Zuie-Chin Huang M.B.A.,
Exec. Chairman -
Mary Thistle,
Independent Director -
Raffaele Baffa,
Chief Medical Officer -
Christopher Taylor,
Vice President, Investor Relations and Corporate Communications -
James Huang,
Director -
J. Kevin Buchi,
Director -
Lynn Ferrucci,
Executive Vice President of Human Resources, Facilities, Administration and IT -
Eleanor De Groot,
Executive Vice President, General Manager, Cell Therapy -
Jill Buck,
Executive Vice President, General Manager, Gene Therapy -
Dr. Drew Deniger,
Head of TCR-T Cell Therapy Program -
Dr. David M. Mauney M.D.,
Consultant -
Melinda Lackey,
Sr. VP of Legal -
Michael Wong,
VP of Fin. & Principal Accounting Officer -
Timothy M. Cunningham CPA, M.B.A.,
Interim CFO & Principal Financial Officer -
Kevin S. Boyle Sr.,
CEO & Director -
James Anthony Cannon,
Director -
Randal Jintrexon Corp Kirk,
-
Murray Brennan,
Director -
Wyche Fowler,
Director -
Randal J Kirk,
Director -
Caesar J Belbel,
COO, CLO, and Secretary -
Michael Weiser,
Director -
Francois Lebel,
Executive Vice President R&D -
David M Md Mauney,
President -
Douglas W. Pagan,
Director -
Scott Braunstein,
Director -
Hagop Youssoufian,
Executive VP, CMO -
Timothy Mcinerney,
Director -
Jonathan Lewis,
CEO -
Jason Amello,
Executive Vice President & CFO -
Richard E Bagley,
President, COO & Treasurer -
George B Abercrombie,
Director -
Robert Peter Gale,
Senior V.P. of Research -
Lindsay A Md Rosenwald,
10% owner -
Woodlands Health Ventures F...,
10% owner -
Gary S Fragin,
Director -
Sath Shukla,
EVP, Chief Financial Officer -
Jaime Vieser,
Director -
Holger Weis,
Director -
Robert W Postma,
Director -
Kevin S. Sr. Boyle,
Chief Executive Officer -
Melinda Lackey,
Senior Vice President, Legal